EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients

Huizi Wu iD, Weiwei Wang, Yinbin Zhang, Yinxi Chen, Changyou Shan, Jia Li, Yiwei Jia, Chaofan Li, Chong Du, Yifan Cai, Yu Zhang, Shuqun Zhang und 1 weitere

International Journal of Cancer · 15.07.2024 · 155 (2) · 324-338

DOI: 10.1002/ijc.34931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 27.03.2024. Verfasst von Huizi Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China. Hauptthemen laut MEDLINE: Organoids, Breast Neoplasms, Precision Medicine, Exome Sequencing. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Construction project of Key Laboratory of Tumor Prevention and Treatment of Integrated Traditional Chinese and Western Medicine of Shaanxi Province, Key Research and Development Program of Shaanxi, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer has become the most commonly diagnosed cancer. The intra‐ and interpatient heterogeneity induced a considerable variation in treatment efficacy. There is an urgent requirement for preclinical models to anticipate the effectiveness of individualized drug responses. Patient‐derived organoids (PDOs) can accurately recapitulate the architecture and biological characteristics of the origin tumor, making them a promising model that can overtake many limitations of cell lines and PDXs. However, it is still unclear whether PDOs‐based drug testing can benefit breast cancer patients, particularly those with tumor recurrence or treatment resistance. Fresh tumor samples were surgically resected for organoid culture. Primary tumor samples and PDOs were subsequently subjected to H&E staining, immunohistochemical (IHC) analysis, and whole‐exome sequencing (WES) to make comparisons. Drug sensitivity tests were performed to evaluate the feasibility of this model for predicting patient drug response in clinical practice. We established 75 patient‐derived breast cancer organoid models. The results of H&E staining, IHC, and WES revealed that PDOs inherited the histologic and genetic characteristics of their parental tumor tissues. The PDOs successfully predicted the patient's drug response, and most cases exhibited consistency between PDOs' drug susceptibility test results and the clinical response of the matched patient. We conclude that the breast cancer organoids platform can be a potential preclinical tool used for the selection of effective drugs and guided personalized therapies for patients with advanced breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsBreast NeoplasmsPrecision MedicineExome SequencingHumansFemaleMiddle AgedAdultAgedDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

breast cancerdrug sensitivity testpatient‐derived organoidspersonalized therapy

Autor:innen und Institutionen

  • Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.

ORCID-Profile: Huizi Wu, Fei Wu

Förderung

  • Construction project of Key Laboratory of Tumor Prevention and Treatment of Integrated Traditional Chinese and Western Medicine of Shaanxi Province
  • Key Research and Development Program of Shaanxi
  • National Natural Science Foundation of China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
  • Key Research and Development Projects of Shaanxi Province

Zitieren

APA

Wu, H., Wang, W., Zhang, Y., Chen, Y., Shan, C., Li, J., Jia, Y., Li, C., Du, C., Cai, Y., Zhang, Y., Zhang, S., & Wu, F. (2024). Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients. International Journal of Cancer, 155(2), 324-338. https://doi.org/10.1002/ijc.34931

Vancouver

Wu H, Wang W, Zhang Y, Chen Y, Shan C, Li J, et al. Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients. International Journal of Cancer. 2024;155(2):324-338. doi:10.1002/ijc.34931

BibTeX
@article{Wu2024,
  author = {Wu, Huizi and Wang, Weiwei and Zhang, Yinbin and Chen, Yinxi and Shan, Changyou and Li, Jia and Jia, Yiwei and Li, Chaofan and Du, Chong and Cai, Yifan and Zhang, Yu and Zhang, Shuqun and Wu, Fei},
  title = {Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {155},
  number = {2},
  pages = {324--338},
  doi = {10.1002/ijc.34931}
}
Kostenlos starten →